[Press Release] Contract Signed for Optimization and Analysis of Toxicity Information Utilizing Daiichi Sankyo and Drug Discovery AI Factory
FRONTEO
FRONTEO Inc. (Headquarters: Minato-ku, Tokyo, President and CEO: Masahiro Morimoto, hereinafter referred to as FRONTEO) announces that it has entered into a contract with Daiichi Sankyo Company, Limited (Headquarters: Chuo-ku, Tokyo, President and COO: Hiroyuki Okuzawa, hereinafter referred to as Daiichi Sankyo) regarding the analysis of a toxicity testing database and the text information of toxicity testing reports utilizing the Drug Discovery AI Factory (hereinafter referred to as DDAIF). Under this contract, FRONTEO will support the introduction of a system that allows for easy confirmation of toxicity interpretations on Daiichi Sankyo's existing toxicity testing database and the construction of an exploratory AI system that aids in the discovery of new insights and ideas through the analysis of toxicity testing reports.
